Log in

NYSE:ABBVAbbVie Stock Price, Forecast & News

$98.88
-0.26 (-0.26 %)
(As of 07/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$97.86
Now: $98.88
$99.99
50-Day Range
$89.94
MA: $93.79
$99.14
52-Week Range
$62.55
Now: $98.88
$99.99
Volume6.59 million shs
Average Volume8.21 million shs
Market Capitalization$146.02 billion
P/E Ratio17.50
Dividend Yield4.77%
Beta0.86
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides KALETRA, an anti-human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; NORVIR, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and SYNAGIS to prevent respiratory syncytial virus infection at-risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron to treat prostate cancer, endometriosis, and central precocious puberty, as well as anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product; and ORILISSA, a non-peptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain. It has collaborations with Alector, Inc.; Janssen Biotech, Inc.; Galapagos; Bristol-Myers Squibb Company; and Calico Life Sciences LLC. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Read More
AbbVie logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.4Community Rank: 2.9Dividend Strength: 5.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.39 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
CUSIP00287Y10
Phone847-932-7900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$33.27 billion
Cash Flow$10.33 per share
Book Value($5.53) per share

Profitability

Net Income$7.88 billion

Miscellaneous

Employees30,000
Outstanding Shares1,476,740,000
Market Cap$146.02 billion
Next Earnings Date7/24/2020 (Estimated)
OptionableOptionable

Receive ABBV News and Ratings via Email

Sign-up to receive the latest news and ratings for ABBV and its competitors with MarketBeat's FREE daily newsletter.

AbbVie (NYSE:ABBV) Frequently Asked Questions

How has AbbVie's stock been impacted by COVID-19 (Coronavirus)?

AbbVie's stock was trading at $84.85 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ABBV shares have increased by 16.5% and is now trading at $98.88. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of AbbVie?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. There are currently 3 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for AbbVie.

When is AbbVie's next earnings date?

AbbVie is scheduled to release its next quarterly earnings announcement on Friday, July 24th 2020. View our earnings forecast for AbbVie.

How were AbbVie's earnings last quarter?

AbbVie Inc (NYSE:ABBV) announced its earnings results on Friday, May, 1st. The company reported $2.42 EPS for the quarter, beating the consensus estimate of $2.25 by $0.17. The business had revenue of $8.62 billion for the quarter, compared to the consensus estimate of $8.31 billion. AbbVie had a net margin of 24.77% and a negative return on equity of 169.80%. AbbVie's revenue was up 10.1% compared to the same quarter last year. During the same quarter last year, the business earned $2.14 EPS. View AbbVie's earnings history.

How often does AbbVie pay dividends? What is the dividend yield for AbbVie?

AbbVie declared a quarterly dividend on Wednesday, June 17th. Stockholders of record on Wednesday, July 15th will be paid a dividend of $1.18 per share on Friday, August 14th. This represents a $4.72 dividend on an annualized basis and a dividend yield of 4.77%. The ex-dividend date of this dividend is Tuesday, July 14th. View AbbVie's dividend history.

How will AbbVie's stock buyback program work?

AbbVie declared that its Board of Directors has approved a share buyback program on Thursday, December 13th 2018, which permits the company to buyback $5,000,000,000.00 in shares, according to EventVestor. This buyback authorization permits the company to repurchase up to 3.8% of its stock through open market purchases. Stock buyback programs are generally a sign that the company's management believes its shares are undervalued.

What guidance has AbbVie issued on next quarter's earnings?

AbbVie updated its FY 2020 After-Hours earnings guidance on Friday, May, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $50-50 billion.

What price target have analysts set for ABBV?

17 Wall Street analysts have issued 12 month price objectives for AbbVie's stock. Their forecasts range from $90.00 to $125.00. On average, they expect AbbVie's share price to reach $106.80 in the next twelve months. This suggests a possible upside of 8.0% from the stock's current price. View analysts' price targets for AbbVie.

Has AbbVie been receiving favorable news coverage?

News articles about ABBV stock have been trending negative on Saturday, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. AbbVie earned a daily sentiment score of -2.8 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 7.0 out of 10, meaning that recent news coverage is likely to have an effect on the stock's share price in the near term. View the latest news about AbbVie.

Who are some of AbbVie's key competitors?

What other stocks do shareholders of AbbVie own?

Who are AbbVie's key executives?

AbbVie's management team includes the following people:
  • Mr. Richard A. Gonzalez, Chairman & CEO (Age 65)
  • Dr. Michael E. Severino, Vice Chairman & Pres (Age 53)
  • Mr. Robert A. Michael, Sr. VP & CFO (Age 49)
  • Mr. William J. Chase, Exec. VP of Fin. & Admin. (Age 51)
  • Ms. Laura J. Schumacher, Vice Chairman of External Affairs, Chief Legal Officer & Corp. Sec. (Age 56)

What is AbbVie's stock symbol?

AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."

Who are AbbVie's major shareholders?

AbbVie's stock is owned by many different institutional and retail investors. Top institutional investors include Park National Corp OH (0.01%), Thomasville National Bank (0.01%), Red Spruce Capital LLC (0.00%), Cox Capital Mgt LLC (0.00%), Smithbridge Asset Management Inc. DE (0.00%) and Nelson Van Denburg & Campbell Wealth Management Group LLC (0.00%). Company insiders that own AbbVie stock include Azita Saleki-Gerhardt, Brian L Durkin, Edward J Rapp, Henry O Gosebruch, Istar Inc, Jeffrey Ryan Stewart, Laura J Schumacher, Michael Severino, Nicholas Donoghoe, Richard A Gonzalez, Roxanne S Austin, Timothy J Richmond and William J Chase. View institutional ownership trends for AbbVie.

Which major investors are selling AbbVie stock?

ABBV stock was sold by a variety of institutional investors in the last quarter, including Park National Corp OH, Birch Capital Management LLC, M&R Capital Management Inc., Red Spruce Capital LLC, Smithbridge Asset Management Inc. DE, and Thomasville National Bank. Company insiders that have sold AbbVie company stock in the last year include Jeffrey Ryan Stewart, and Timothy J Richmond. View insider buying and selling activity for AbbVie.

Which major investors are buying AbbVie stock?

ABBV stock was bought by a variety of institutional investors in the last quarter, including Nelson Van Denburg & Campbell Wealth Management Group LLC, Modus Advisors LLC, Cox Capital Mgt LLC, and Ellenbecker Investment Group. Company insiders that have bought AbbVie stock in the last two years include Brian L Durkin, Edward J Rapp, Henry O Gosebruch, Istar Inc, Jeffrey Ryan Stewart, Laura J Schumacher, Nicholas Donoghoe, Roxanne S Austin, and William J Chase. View insider buying and selling activity for AbbVie.

How do I buy shares of AbbVie?

Shares of ABBV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is AbbVie's stock price today?

One share of ABBV stock can currently be purchased for approximately $98.88.

How big of a company is AbbVie?

AbbVie has a market capitalization of $146.02 billion and generates $33.27 billion in revenue each year. The company earns $7.88 billion in net income (profit) each year or $8.94 on an earnings per share basis. AbbVie employs 30,000 workers across the globe.

What is AbbVie's official website?

The official website for AbbVie is www.abbvie.com.

How can I contact AbbVie?

AbbVie's mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. The company can be reached via phone at 847-932-7900.

This page was last updated on 7/4/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.